2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Dexamethasone
882
Bortezomib
481
Lenalidomide
467
Cyclophosphamide
367
Melphalan
276
Calcium Dobesilate
265
daratumumab
241
pomalidomide
216
carfilzomib
188
fludarabine phosphate
141
fludarabine
137
Thalidomide
125
Peripheral Blood Stem Cell Transplantation
120
Filgrastim
115
ixazomib
94
Mycophenolic Acid
91
Granulocyte Colony-Stimulating Factor
90
Busulfan
89
Whole-Body Irradiation
88
dexamethasone acetate
87
Tacrolimus
79
dexamethasone 21-phosphate
74
isatuximab
70
Cyclosporine
68
auricularum
67
Prednisone
67
elotuzumab
63
belantamab mafodotin
60
Antilymphocyte Serum
56
Etoposide
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
ogalvibart
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn